Loading...

Paratek Pharmaceuticals ($PRTK)

Stock Image

PRTK Overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.The company has license and collaboration agreements with Zai Lab (Shanghai) Company and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases.Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Paratek Pharmaceuticals

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.